Abstract:We report on the frequency of liver tumors observed in a gene therapy study with AAV vectors in male mice of the B6C3F1 hybrid background, which are known to have a high frequency of spontaneous tumor formation in the liver. Because of their increased susceptibility to develop tumors, these animals should serve as sensitive models to reveal any potential tumorigenic properties of AAV vectors. Male mice with mutations in their OTC gene (spf and spf-ash) and their wild-type siblings had received AAV vectors expressing either the murine OTC (mOTC) or LacZ gene. Untreated control animals were included in the study. All experimental groups including wild-type and mOTC-deficient animals not treated with vector developed liver nodules. In the majority of the animals, H&E-stained liver samples were available that allowed to score the observed nodules according to their likelihood to represent hepatocellular carcinomas. In the spf group no statistically significant risk differences were found between vector-treated and untreated animals. Likewise, in the spf-ash group the administration of vectors expressing mOTC did not increase the risk of tumor development. However, these mice showed increased risks of tumor formation when treated with LacZ-expressing vectors compared to untreated animals or animals that had received vectors with mOTC as transgene, suggesting that the transgene but not the vector might play a role in the formation of tumors. In general, both the overall risk of developing liver nodules and the histological appearance as hepatocellular carcinoma was more frequent in mice that had received AAV-LacZ compared to untreated controls or animals treated with AAVmOTC. Tumor tissue contained consistently lower amounts of vector DNA than healthy liver tissue, and only one out of 16 tumors was found to express the transgene as determined by histochemistry to detect OTC activity and immunostaining against beta-galactosidase. We therefore conclude that AAV vectors alone do not contribute to the formation of tumors, even in mouse strains with a heightened susceptibility to the development of those lesions. However, the expression of LacZ alone or in combination with vector may be problematic.

Prevention of Portal-Tract Fibrosis in Zfyve19-/- Mouse Model with Adeno-Associated Virus Vector Delivering ZFYVE19

ZFYVE19 deficiency: a ciliopathy involving failure of cell division, with cell death

Vascular Endothelial Growth Factor Attenuates Hepatic Sinusoidal Capillarization in Thioacetamide-Induced Cirrhotic Rats

Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 9 in a symptomatic mouse model

Enhancing transduction of the liver by adeno-associated viral vectors

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Adeno-associated virus as a vector for liver-directed gene therapy

Attenuation Of Experimental Liver Fibrosis By Hepatocyte Growth Factor Gene Delivery Mediated By Adenovirus

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice

Adeno-associated Virus Mediated Interferon-Gamma Inhibits the Progression of Hepatic Fibrosis in Vitro and in Vivo.

Biallelic Loss-of-function ZFYVE19 Mutations Are Associated with Congenital Hepatic Fibrosis, Sclerosing Cholangiopathy and High-Ggt Cholestasis

Gene therapy for human α1-antitrypsin deficiency in an animal model using SV40-Derived vectors

Development of Optimized AAV3 Serotype Vectors: Mechanism of High-Efficiency Transduction of Human Liver Cancer Cells

Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

Directed evolution of adeno-associated virus 5 capsid enables specific liver tropism

A humanized mouse model for adeno-associated viral gene therapy

Truncated active human matrix metalloproteinase-8 delivered by a chimeric adenovirus-hepatitis B virus vector ameliorates rat liver cirrhosis.

206. Frequency and Analysis of Liver Tumors in AAV-Treated B6C3F1 Hybrid Mice

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor